In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease

In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease

Saved in:
Bibliographic Details
Main Authors: Michal Geva, Ralf Reilmann, Robin Schubert, Kelly Chen, Y Paul Goldberg, Michael R. Hayden
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Neurotherapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S1878747925001540
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items